Streptococcus suis polypeptides and polynucleotides encoding same and their use in vaccinal and diagnostic applications

ABSTRACT

The present invention relates to the field of Streptococcus. More specifically, the present invention relates to the identification of polypeptides and polynucleotide sequences encoding the same which are involved in the pathogenic mechanism of S. suis. The present invention also relates to the use of such polypeptides in compositions and methods for the prevention, the treatment and diagnosis of S. suis-associated diseases and infections caused by S. suis.

This is an application for reissue of U.S. Pat. No. 7,927,608, and is a reissue continuation of application Ser. No. 14/634,396, now reissue Pat. No. RE46,285, which is a reissue divisional of application Ser. No. 13/866,780, which is also an application for reissue of U.S. Pat. No. 7,927,608, now reissue Pat. No. RE45,467.

FIELD OF THE INVENTION

The present invention relates to the field of Streptococcus. More specifically, the present invention relates to the identification of polypeptides and polynucleotide sequences encoding the same which are involved in the pathogenic mechanism of S. suis. The present invention also relates to the use of such polypeptides in compositions and methods for the prevention, the treatment and diagnosis of S. suis-associated diseases and infections caused by S. suis.

SEQUENCE LISTING

In accordance with 37 CFR §1.52(e)(5), the present specification makes reference to a Sequence Listing (submitted electronically as a .txt file named “SeqListing.txt” on Jan. 31, 2011 Feb. 27, 2015). The .txt file was generated on Jan. 20, 2011 and is 40 Jan. 13, 2014 and is 48 kb in size. The entire contents of the Sequence Listing are herein incorporated by reference.

BACKGROUND OF THE INVENTION

Streptococcus suis is an important swine pathogen that causes many pathological conditions such as arthritis, endocarditis, meningitis, pneumonia and septicemia (13, 14). It is also an important zoonotic agent for people in contact with contaminated pigs or their by-products, causing meningitis and endocarditis (1, 36). Thirty-three serotypes (types 1 to 31, 33 and 1/2) based on capsular antigens are currently known (9-11, 15, 17, 31). Type 2 is considered the most virulent and prevalent type in diseased pigs. The mechanisms involved in the pathogenesis and virulence of S. suis are not completely understood (13) and attempts to control the infection are hampered by the lack of effective vaccines.

Several approaches have been made to develop vaccines for S. suis. However, little success was achieved because the protection was either serotype or strain dependent and results, in most instances, were equivocal (16, 30). For example, some protection with killed whole cells and live avirulent vaccines were reported, but this required repeated immunization and the protection against heterologous challenges was not determined (18, 38). Exposure of young pigs with live virulent strains showed a positive effect in reducing clinical signs characteristics of S. suis infection, but not in central nervous sign and mortality (35). Since the S. suis capsule plays an important role in virulence, attempts have been made to develop a vaccine based on capsular material. However, this vaccination was unsatisfactory because the capsular polysaccharide is poorly immunogenic (7). More recently, interest has shifted toward protein antigens of S. suis as vaccine candidates. Subunit vaccines using suilysin (20), or MRP (muramidase-released protein) and EF (extracellular proteins factor) (39) have been shown to protect pigs from homologous and heterologous serotype 2 strains, but their use is hindered by the fact that a substantial number of the virulent strains in some geographical regions do not express these proteins (8, 12, 29). Thus, identification of other antigenic factors, especially surface proteins, could contribute to the development of a subunit vaccine.

There is thus a need for the discovery and use of new targets for the prevention, the treatment and the diagnosis of S. suis-associated diseases and infections caused by S. suis.

SUMMARY OF THE INVENTION

An object of the invention is to fulfill the above-mentioned need. More specifically, the object is achieved by providing an isolated polypeptide comprising at least 15 contiguous amino acids in the N-terminal region of the amino acid sequence set forth in SEQ ID NO: 1.

Another object of the invention also concerns an polynucleotide encoding a polypeptide as defined above.

The present invention is further concerned with an antibody which specifically binds to a polypeptide of the invention.

A further object of the invention is to provide a vector comprising the polynucleotide as defined above.

Yet another object of the invention is to provide a composition for preventing or treating Streptococcus suis-associated diseases or infection caused by S. suis, comprising an acceptable carrier and at least one of the following elements:

-   -   a polypeptide as defined above;     -   a polypeptide as defined above;     -   an antibody as defined above;     -   a vector as defined above.

Another object of the invention concerns a method for treating and/or preventing a Streptococcus suis-associated disease or infection in an animal, the method comprising the step of administering to the animal a composition as defined above.

A further object concerns a method for detecting the presence or absence of a Streptococcus suis strain in a sample, comprising the steps of:

-   -   a) contacting the sample with an antibody of the invention for a         time and under conditions sufficient to form an immune complex;         and     -   b) detecting the presence or absence of the immune complex         formed in a).

Another object of the invention concerns a method for detecting the presence or absence of antibodies raised against a Streptococcus suis strain in a sample, comprising the steps of:

-   -   a) contacting the sample with a polypeptide of the invention for         a time and under conditions sufficient to form an immune         complex; and     -   b) detecting the presence or absence of the immune complex         formed in a).

The present invention also provide in another object a diagnostic kit for the detection of the presence or absence of antibodies indicative of Streptococcus suis strain, comprising:

-   -   a polypeptide according to the invention;     -   a reagent to detect polypeptide-antibody immune complex;     -   a biological reference sample lacking antibodies that         immunologically bind with said peptide; and     -   a comparison sample comprising antibodies which can specifically         bind to said peptide;         wherein said polypeptide, reagent, biological reference sample,         and comparison sample are present in an amount sufficient to         perform said detection.

Yet another object is to provide a diagnostic kit for the detection of the presence or absence of antibodies indicative of Streptococcus suis strain, comprising:

-   -   an antibody of the invention;     -   a reagent to detect polypeptide-antibody immune complex;     -   a biological reference sample polypeptides that immunologically         bind with said antibody; and     -   a comparison sample comprising polypeptides which can         specifically bind to said peptide;         wherein said antibody, reagent, biological reference sample, and         comparison sample are present in an amount sufficient to perform         said detection.

Further objects are to provide an isolated polypeptide comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO 11 or functional derivative thereof, and an isolated polynucleotide encoding said polypeptide, and their use in a composition and/or a method for treating and/or preventing a Streptococcus suis-associated disease or infection in an animal.

BRIEF DESCRIPTION OF THE FIGURES

Unless specifically indicated to the contrary, the terms “SP1” and “Sao” are used interchangeably.

FIG. 1: Schematic representation and partial restriction map of a preferred polynucleotide of the invention, namely the DNA insert of recombinant plasmid pSS735. Numbers indicate the distance (in base pairs) from the 5′ end.

FIG. 2: Nucleotide sequence (SEQ ID NO: 5)(SEQ ID NO: 20) and deduced amino acid sequence (SEQ ID NO: 1)(SEQ ID NO: 19) of the gene encoding a preferred polypeptide of a first embodiment of the invention, namely the SP1 (or Sao) protein of S. suis. The Shine-Dalgarno sequence is in italic letters and underlined. The initiation codon, ATG, and the stop codon, TAA, are shown in bold type. The two hydrophobic segments at the both N- and C-terminal ends of SP1 are underlined. The vertical arrow indicates the cleavage site of potential signal peptidase. R1 to R10 indicate the beginning of the repeating units. The potential cell wall-associated region is underlined with dash line. The LPVTG (SEQ ID NO: 10) membrane anchor motif is boxed, and the charged C-terminal tail is indicated.

FIG. 3: Amino acid sequence alignment of the region Lys³¹⁹ to Val⁶⁰¹ of SP1 (SEQ ID NO: 18) with the AvrXa7 avirulence factor of Xanthomonas oryzae pv. oryzae (SEQ ID NO: 17). The vertical lines indicate positions with identical residues. Double dots represent conserved substitutions and single dots represent functional substitutions.

FIG. 4: Expression of MBP-SP1 fusion protein in E. coli XL1-Blue and purification of the recombinant mature SP1. The Coomassie-stained gel (A) and Western blot analysis (B) of the corresponding samples probed with convalescent swine serum show E. coli whole cell lysate before (lane 1) and after (lane 2) induction of IPTG, extract of cytoplasm (lane 3), affinity purified MBP-SP1 fusion protein (lane 4), SP1 and MBP cleaved by factor X (lane 5) and recombinant SP1 devoid of MBP purified using ion-exchange chromatography (lane 6). The molecular masses of standard proteins are indicated on the left.

FIG. 5: Immunoelectron microscopy of S. suis (4500×). The surface location of SP1 on S. suis is demonstrated using a monospecific SP1 antiserum and a gold-conjugated secondary antibody (B). No labeling was found in the control bacterial cell (A). Bars, 200 nm.

FIG. 6: Antibody responses after vaccination with the SP1 in piglets. (A) Total SP1-specific IgG in sera was measured by ELISA, showing that single injection of SP1 elicited a significant IgG response that was obviously enhanced by the booster. (B) ELISA for serum IgG isotypes in SP1 immunized pigs showed that IgG1 levels were consistently higher than IgG2 levels. The results are expressed as the means of absorbances and standard errors. *: p≤0.05.

FIG. 7: SP1-specific total humoral IgG titres in mice immunized with Quil A and Quil A plus SP1.

FIG. 8: IgG subclasses in sera from mice immunized with recombinant SP1.

FIG. 9: Vaccination with recombinant SP1 protects mice against S. suis challenge infection.

FIG. 10: Vaccination with recombinant SP1 protects mice from S. suis death.

FIG. 11: Nucleotide sequence (SEQ ID NO: 8) of a preferred functional polynucleotide fragment of the invention, namely the SP1A gene fragment and the deduced amino acid sequences (SEQ ID NO: 4).

FIG. 12: Schematic representation and partial restriction map of the 6.3 kb insert of recombinant phage. Numbers indicate the distance (in base pairs) from the 5′ end.

FIG. 13: Nucleotide sequence (SEQ ID NO: 12) and deduced amino acid sequence (SEQ ID NO: 11) of the gene encoding a preferred polypeptide of another embodiment of the invention, namely the SP2 protein of S. suis. The positive charge cluster at N-terminal end of SP2 is underlined. The potential N-terminal signal sequence is underlined with dash line. The LysM domain is boxed, and the arrows indicate the beginning of the repeating units.

FIG. 14: Distribution of SP2 gene in different S. suis serotypes. The SP2 genes were amplified by PCR from 31 of the 33 S. suis serotype reference strains.

FIG. 15: Expression of Trx-His-SP2 fusion protein in E. coli and purification of the recombinant mature SP2. The Coomassie-stained gel shows E. coli whole cell lysate after induction of IPTG, affinity purified Trx-His-SP2 fusion protein, SP2 and Trx-His cleaved by enterokinase, separated mature SP2 and Trx-His tag by an anion-exchange chromatography. The molecular masses are indicated on the left.

FIG. 16: Immunogenic and IgG-binding activity of recombinant SP2. a) SP2-specific rabbit serum reacts with the cell preparation of S. suis S735. b) Recombinant SP2 reacts with the convalescent swine serum. Recombinant SP2 binds to human (c) and pig (d) IgG.

FIG. 17: Antibody response after vaccination with recombinant SP2 in mice. SP2-specific IgG in sera was measured by ELISA.

FIG. 18: Vaccination with recombinant SP2 alleviates clinical signs of the mice challenged with a virulent S. suis strain.

FIG. 19: Vaccination with recombinant SP2 protects mice from S. suis death.

FIG. 20: Body temperature of pigs vaccinated with the composition according to a preferred embodiment of the invention, after challenge.

FIG. 21: Clinical disease of pigs vaccinated with the composition according to a preferred embodiment of the invention, after challenge.

FIG. 22: Survival of pigs vaccinated with the composition according to a preferred embodiment of the invention, after challenge.

FIG. 23: Serum total IgG titers of pigs vaccinated with the composition according to a preferred embodiment of the invention.

FIG. 24: IgG subclasses induced from pigs vaccinated with the composition according to a preferred embodiment of the invention.

FIG. 25: Amino acid sequence alignment between two SP1 polypeptides according to preferred embodiments of the invention, namely SEQ ID NO 1 and 2.

FIG. 26: Amino acid sequence alignment between two SP1 polypeptides according to preferred embodiments of the invention, namely SEQ ID NO 1 and 3.

FIG. 27: Amino acid sequence alignment between two SP1 polypeptides according to preferred embodiments of the invention, namely SEQ ID NO 2 and 3.

FIG. 28: Amino acid sequence alignment between three SP1 polypeptides according to preferred embodiments of the invention, namely SEQ ID NO 1, 2 and 3.

BRIEF DESCRIPTION OF THE INVENTION

The inventors have surprisingly found two novel S. suis polypeptides and polynucleotides encoding same that are involved during the S. suis pathogenic mechanism. In this connection, the present invention specifically relates to their identification and to the use of said polypeptides or polynucleotides in compositions and methods for the prevention, the treatment and the diagnosis of Streptococcus suis-associated diseases or infection caused by S. suis.

A non-exhaustive list of Streptococcus suis-associated diseases which the methods of the invention may be useful for, includes those, such as arthritis, endocarditis, meningitis, pneumonia and septicemia.

Definitions

The term “isolated” is meant to describe a polynucleotide, a polypeptide or an antibody that is in an environment different from that in which the polynucleotide, the polypeptide, the antibody, or the host cell naturally occurs.

The term “animal” refers to any animal susceptible to be infected by a Streptococcus strain, such as S. suis. Specifically, such an animal may be, but not limited to, mice, pig, sheep, horse and human. More specifically, the animal consists of a pig.

The term “treating” refers to a process by which the symptoms of an infection or a disease associated with a Streptococcus strain are alleviated or completely eliminated. As used herein, the term “preventing” refers to a process by which symptoms of an infection or a disease associated with a Streptococcus strain are obstructed or delayed.

The term “protective response” means prevention of onset of a Streptococcus suis-associated disease or an infection caused by S. suis. or lessening the severity of such a disease existing in an animal. The level of “protective response” may be evaluated, for instance, by the assignment of clinical scores such as those defined in Example 4.

The expression “an acceptable carrier” means a vehicle for containing the compounds obtained by the method of the invention that can be administered to an animal host without adverse effects. Suitable carriers known in the art include, but are not limited to, gold particles, sterile water, saline, glucose, dextrose, or buffered solutions. Carriers may include auxiliary agents including, but not limited to, diluents, stabilizers (i.e., sugars and amino acids), preservatives, wetting agents, emulsifying agents, pH buffering agents, viscosity enhancing additives, colors and the like.

The term “fragment”, as used herein, refers to a polynucleotide sequence (e.g., cDNA) which is an isolated portion of the subject nucleic acid constructed artificially (e.g., by chemical synthesis) or by cleaving a natural product into multiple pieces, using restriction endonucleases or mechanical shearing, or a portion of a nucleic acid synthesized by PCR, DNA polymerase or any other polymerizing technique well known in the art, or expressed in a host cell by recombinant nucleic acid technology well known to one of skill in the art.

1 Polynucleotides and Polypeptides of the Invention

In a first embodiment, the present invention concerns an isolated polypeptide which consists of a surface protein, and more particularly a C-terminal-anchored surface protein of Streptococcus suis, namely called SP1 or Sao (Genbank accession number AY864331). As shown in the Example section, the SP1 polypeptide advantageously elicits a protective response to a Streptococcus suis strain challenge when administered to an animal, such as a pig.

Specifically, the isolated polypeptide of the first embodiment of the invention comprises at least 15 or even preferably at least 25 or even more at least 35 contiguous amino acids in the N-terminal region of the amino acid sequence set forth in SEQ ID NO: 1. As one skilled in the art may appreciate, the term “N-terminal region” in the context of the present invention when referring to the Sao protein, preferably consists of the region spanning from amino acid residue 1 to 293 of the amino acid sequence set forth in SEQ ID NO: 1.

According to a preferred embodiment, the isolated polypeptide of the first embodiment may further comprises at least one repetitive amino acid sequence such as shown in FIG. 2. More particularly, a repetitive amino acid sequence contemplated by the present invention consists of the amino acid sequence shown in SEQ ID NO 9,

wherein

-   -   Xaa₁ is Val, Thr or Ile;     -   Xaa₃ is Lys or Glu;     -   Xaa₄ is Lys or Glu;     -   Xaa₅ is Ala or Gln;     -   Xaa₇ is Thr or Pro;     -   Xaa₈ is Gly, Ser or Val;     -   Xaa₉ is Lys, Val, Ile or Asn;     -   Xaa₁₀ is Glu or Val;     -   Xaa₁₁ is Lys or Asn;     -   Xaa₁₂ is Gly, Glu or Asp;     -   Xaa₁₃ is Asn or Met;     -   Xaa₁₄ is Ile, Ala or Val;     -   Xaa₁₅ is Glu or Val;     -   Xaa₁₆ is Pro or Thr;     -   Xaa₁₈ is Glu or Gln;     -   Xaa₁₉ is Lys or Glu;     -   Xaa₂₂ is Thr or Ala     -   Xaa₂₆ is Lys or Asn;     -   Xaa₂₇ is Asp or Glu;     -   Xaa₂₈ is Asn or Lys;     -   Xaa₂₉ is Ile or Val and     -   Xaa₃₀ is Glu or Val.

It will be understood that the preferred SP1 polypeptide of the invention may comprises only one of said repetitive sequence, whereas in some other cases, the preferred SP1 polypeptide of the invention may comprises at least two repetitive sequences or even more than ten of such repetitive sequences.

In accordance with another preferred embodiment of the invention, the isolated SP1 polypeptide advantageously comprises at least 15 or even preferably 25 or even more preferably 35 contiguous amino acids in the C-terminus region of the amino acid sequence set forth in SEQ ID NO: 1. Preferably, the C-terminus region comprises a membrane anchor motif, such as the one consisting of the amino acid sequence as set forth is SEQ ID NO 10, namely Leu Pro Val Thr Gly.

As one skilled in the art may appreciate, the term “C-terminus region” in the context of the present invention when referring to the SP1 protein, preferably consists of the region spanning from amino acid residue 593 to 670 of the amino acid sequence set forth in SEQ ID NO: 1.

In accordance with an even more preferred embodiment, a SP1 polypeptide of the invention comprises an amino acid sequence substantially identical to a sequence selected from the group consisting of SEQ ID NOS 1 to 3 or functional derivative thereof. Most preferably, a SP1 polypeptide of the invention consists of an amino acid sequence substantially identical to the sequence shown in SEQ ID NO 1, or a functional derivative thereof.

A “functional derivative”, as is generally understood and used herein, refers to a protein/peptide sequence that possesses a functional biological activity that is substantially similar to the biological activity of the whole protein/peptide sequence. In other words, it preferably refers to a polypeptide or fragment(s) thereof that substantially retain(s) the capacity of eliciting an immune response, such as a protective response to a S. suis strain challenge when said functional derivative is administered to an animal. A preferred functional derivative contemplated by the present invention comprises an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO 4. More specifically, a preferred functional derivative consists of a 315-amino acids fragment (S²⁸-K³⁴²) of SEQ ID NO 1. Such a fragment or polypeptide is designed as SP1A and its nucleotide and amino acid sequences are shown in FIG. 11. SP1A strongly reacted with a convalescent swine serum in immunoblots and immunization with recombinant SP1A elicits significant humoral antibody responses in pigs and mice, demonstrating that SP1A is highly immunogenic. (See Example 5)

According to a second embodiment, the present invention relates to another isolated S. suis polypeptide, namely called SP2, which advantageously elicits a protective response in an animal.

Specifically, the isolated polypeptide of the second embodiment of the invention comprises an amino acid sequence substantially identical to a sequence as set forth in SEQ ID NO: 11 or functional derivative thereof.

By “substantially identical” when referring to an amino acid sequence, it will be understood that the polypeptide of the present invention preferably has an amino acid sequence having at least 75% homology, or even preferably 85% homology, or even more preferably 95% homology to part or all of the sequence shown in SEQ ID NOS 1 to 4 and 11.

“Homology” in this context, means identical or similar to the referenced sequence while straightforward replacements/modifications of any of the amino acids provided, are included as well. A homology search in this respect can be performed with the BLAST-P (Basic Local Alignment Search Tool), a program well known to those of skill in the art. For the corresponding nucleic acid sequence, homology is referred to the BLASTX and BLASTN programs known in the art.

The present invention also concerns an isolated polynucleotide encoding a preferred SP1 or a preferred SP2 polypeptide of the invention. Preferably, the isolated polynucleotide of the invention comprises a nucleotide sequence substantially identical to the sequence shown in SEQ ID NOS 5 to 7 when referring to SP1 and SEQ ID NO 12 when referring to SP2 and their respective functional fragments thereof.

By “substantially identical” when referring to a nucleic acid sequence, it will be understood that the polynucleotide of the invention preferably has a nucleic acid sequence which is at least 65% identical, more particularly 80% identical and even more particularly 95% identical to part or all of the sequence shown in SEQ ID NOS 5 to 7 and 12 or functional fragments thereof.

A “functional fragment”, as is generally understood and used herein, refers to a nucleic acid sequence that encodes for a functional biological activity that is substantially similar to the biological activity of the whole nucleic acid sequence. In other words, and within the context of the present invention, it preferably refers to a nucleic acid or fragment(s) thereof that substantially retains the capacity of encoding a polypeptide/protein which elicits an immune response, and more preferably a protective response, to a Streptococcus suis strain challenge when administered to an animal. For instance, such a fragment is the polynucleotide shown in SEQ ID NO 8, which codes for the SP1A polypeptide as defined above.

In another embodiment, the invention is further directed to vector (e.g., cloning or expression vector) comprising a polynucleotide of the invention as defined above.

As used herein, the term “vector” refers to a polynucleotide construct designed for transduction/transfection of one or more cell types. Vectors may be, for example, “cloning vectors” which are designed for isolation, propagation and replication of inserted nucleotides, “expression vectors” which are designed for expression of a nucleotide sequence in a host cell, or a “viral vector” which is designed to result in the production of a recombinant virus or virus-like particle, or “shuttle vectors”, which comprise the attributes of more than one type of vector.

A number of vectors suitable for stable transfection of cells and bacteria are available to the public (e.g., plasmids, adenoviruses, baculoviruses, yeast baculoviruses, plant viruses, adeno-associated viruses, retroviruses, Herpes Simplex Viruses, Alphaviruses, Lentiviruses), as are methods for constructing such cell lines. It will be understood that the present invention encompasses any type of vector comprising any of the polynucleotide molecule of the invention.

2. Antibodies

In another embodiment, the invention features antibodies that specifically bind to the polypeptides of the invention. More specifically, the antibody is a purified polyclonal or monoclonal antibody that specifically binds to the preferred S. suis polypeptides as defined above.

The antibodies of the invention may be prepared by a variety of methods known to one skilled in the art. For example, the polypeptides of the invention may be administered to an animal in order to induce the production of polyclonal antibodies. Alternatively, and as mentioned above, antibodies used as described herein may be monoclonal antibodies, which are prepared using known hybridoma technologies (see, e.g., Hammerling et al., In Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., 1981; Charland, N., M. Jacques, S. Iacouture and M. Gottschalk. 1997. Characterization and protective activity of a monoclonal antibody against a capsular epitope shared by Streptococcus suis serotypes 1, 2 and ½. Microbiology 143 (Pt 11): 3607-14).

With respect to antibodies of the present invention, the term “specifically binds to” refers to antibodies that bind with a relatively high affinity to one or more epitopes of the SP1 or SP2 polypeptide of the invention, but which do not substantially recognize and bind molecules other than the SP1 or SP2 polypeptides of the invention. As used herein, the term “relatively high affinity” means a binding affinity between the antibody and the SP1 or SP2 polypeptides of at least 10⁶ M⁻¹, and preferably of at least about 10⁷ M⁻¹ and even more preferably 10⁸ M⁻¹ to 10¹⁰ M⁻¹. Determination of such affinity is preferably conducted under standard competitive binding immunoassay conditions which are common knowledge to one skilled in the art.

3. Methods of Treatment and Compositions

The SP1 and SP2 polypeptides, polynucleotides encoding same and antibodies of the invention may be used in many ways in the treatment and/or prevention of Streptococcus suis-associated diseases or infection caused by S. suis.

For instance, and according to an aspect of the invention, the SP1 and/or SP2 polypeptides of the invention may be used as immunogens for the production of specific antibodies for the treatment and/or prevention of Streptococcus suis infection. Suitable antibodies may be determined using appropriate screening methods, for example by measuring the ability of a particular antibody to passively protect against Streptococcus suis infection in a test model. Examples of an animal model are the mouse and pig models described in the examples herein.

According to another aspect, the polynucleotides encoding polypeptides of the invention or derivatives thereof may be used in a DNA immunization method. That is, they can be incorporated into a vector which is replicable and expressible upon injection thereby producing the antigenic polypeptide in vivo. For example polynucleotides may be incorporated into a plasmid vector under the control of the CMV promoter which is functional in eukaryotic cells. Preferably the vector is injected intramuscularly.

The use of a polynucleotide of the invention in genetic immunization will preferably employ a suitable delivery method or system such as direct injection of plasmid DNA into muscles [Wolf et al. H M G (1992) 1: 363, Turnes et al., Vaccine (1999), 17: 2089, Le et al., Vaccine (2000) 18: 1893, Alves et al., Vaccine (2001)19: 788], injection of plasmid DNA with or without adjuvants [Ulmer et al., Vaccine (1999) 18: 18, MacLaughlin et al., J. Control Release (1998)56: 259, Hartikka et al., Gene Ther. (2000)7: 1171-82, Benvenisty and Reshef, PNAS USA (1986) 83: 9551, Singh et al., PNAS USA (2000) 97: 811], targeting cells by delivery of DNA complexed with specific carriers [Wa et al., J Biol Chem (1989) 264: 16985, Chaplin et al., Infect. Immun. (1999) 67:6434], injection of plasmid complexed or encapsulated in various forms of liposomes [Ishii et al., AIDS Research and Human Retroviruses (1997) 13: 142, Perrie et al., Vaccine (2001) 19:3301], administration of DNA with different methods of bombardment [Tang et al., Nature (1992) 356: 152, Eisenbraun et al., DNA Cell Biol (1993) 12: 791, Chen et al., Vaccine (2001) 19:2908], and administration of DNA with lived vectors [Tubulekas et al., Gene (1997) 190: 191, Pushko et al., Virology (1997) 239: 389, Spreng et al. FEMS (2000) 27: 299, Dietrich et al., Vaccine (2001) 19: 2506].

A further aspect of the invention is the use of the antibodies directed to the polypeptides of the invention for passive immunization. One could use the antibodies described in the present application.

In this connection, another embodiment of the present invention relates to a composition for preventing or treating such diseases or infections. The composition of the present invention advantageously comprises an acceptable carrier and a SP1 and/or SP2 polypeptide(s) of the invention. Alternatively, the composition of the invention can comprise an antibody and/or a polynucleotide and/or an expression vector of the invention.

In a preferred embodiment, the composition of the invention further comprises an adjuvant. As used herein, the term “adjuvant” means a substance added to the composition of the invention to increase the composition's immunogenicity. The mechanism of how an adjuvant operates is not entirely known. Some adjuvants are believed to enhance the immune response (humoral and/or cellular response) by slowly releasing the antigen, while other adjuvants are strongly immunogenic in their own right and are believed to function synergistically. Known adjuvants include, but are not limited to, oil and water emulsions (for example, complete Freund's adjuvant and incomplete Freund's adjuvant), Corytzebactei-ium parvuin, Quil A, cytokines such as IL12, Emulsigen-Plus®, Bacillus Calmette Guerin, aluminum hydroxide, glucan, dextran sulfate, iron oxide, sodium alginate, Bacto Adjuvant, certain synthetic polymers such as poly amino acids and co-polymers of amino acids, saponin, paraffin oil, and muramyl dipeptide. Adjuvants also encompass genetic adjuvants such as immunomodulatory molecules encoded in a co-inoculated DNA, or as CpG oligonucleotides. The coinoculated DNA can be in the same plasmid construct as the plasmid immunogen or in a separate DNA vector.

Yet, a further embodiment of the present invention is to provide a method for treating and/or preventing a Streptococcus suis-associated disease or infection in an animal. The method of the invention comprises the step of administering to the animal a composition according to the invention.

Further agents can be added to the composition of the invention. For instance, the composition of the invention may also comprise agents such as drugs, immunostimulants (such as α-interferon, β-interferon, γ-interferon, granulocyte macrophage colony stimulator factor (GM-CSF), macrophage colony stimulator factor (M-CSF), and interleukin 2 (IL2)), antioxidants, surfactants, flavoring agents, volatile oils, buffering agents, dispersants, propellants, and preservatives. For preparing such compositions, methods well known in the art may be used.

The amount of the components or the elements of the composition of the invention is preferably a therapeutically effective amount. A therapeutically effective amount of the contemplated component is the amount necessary to allow the same to perform their immunological role without causing overly negative effects in the host to which the composition is administered. The exact amount of the components to be used and the composition to be administered will vary according to factors such as the type of condition being treated, the type and age of the animal to be treated, the mode of administration, as well as the other ingredients in the composition.

The composition of the invention may be given to an animal through various routes of administration. For instance, the composition may be administered in the form of sterile injectable preparations, such as sterile injectable aqueous or oleaginous suspensions. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparations may also be sterile injectable solutions or suspensions in non-toxic parenterally-acceptable diluents or solvents. They may be given parenterally, for example intravenously, intramuscularly or sub-cutaneously by injection, by infusion or per os. Suitable dosages will vary, depending upon factors such as the amount of each of the components in the composition, the desired effect (short or long term), the route of administration, the age and the weight of the animal to be treated. Any other methods well known in the art may be used for administering the composition of the invention.

4. Methods of Detection or Diagnosis and Kits

The SP1 and/or SP2 polypeptides, polynucleotides encoding same and antibodies of the invention may also be used in different ways in the detection and diagnosis of Streptococcus suis-associated diseases or infections caused by S. suis.

In this connection and in a further embodiment, the present invention provides a method for detecting the presence or absence of a Streptococcus suis strain in a sample, comprising the steps of:

-   -   a) contacting the sample with an antibody of the invention as         defined above for a time and under conditions sufficient to form         a complex; and     -   b) detecting the presence or absence of the complex formed in         a).

As used herein, the term “sample” refers to a variety of sample types obtained from an animal and can be used in a diagnostic or detection assay. The definition encompasses blood and other liquid samples of biological origin, solid tissue samples such as a biopsy specimen or tissue culture or cells derived therefrom.

Yet, in another embodiment, the present invention provides a method for detecting the presence or absence of antibodies raised against a Streptococcus suis strain in a sample, comprising the steps of:

-   -   a) contacting the sample with a polypeptide of the invention as         defined above for a time and under conditions sufficient to form         an immune complex; and     -   b) detecting the presence or absence of the immune complex         formed in a).

One skilled in the art will recognize that this diagnostic test may take several forms, including an immunological test such as an enzyme-linked immunosorbent assay (ELISA) or a radioimmunoassay, essentially to determine whether antibodies specific for the protein (such as SP1 and/or SP2) are present in an organism.

The present invention further provides kits for use within any of the above diagnostic methods. Such kits typically comprise two or more components necessary for performing a diagnostic assay. Components may be compounds, reagents, containers and/or equipment. For example, one container within a kit may contain an antibody or fragment thereof that specifically binds to a SP1 or SP2 polypeptide of the invention. One or more additional containers may enclose elements, such as reagents or buffers, to be used in the assay.

In this connection, the present invention also provides a diagnostic kit for the detection of the presence or absence of antibodies indicative of Streptococcus suis strain, comprising:

-   -   a SP1 and/or SP2 polypeptide according to the invention;     -   a reagent to detect polypeptide-antibody immune complex;     -   a biological reference sample lacking antibodies that         immunologically bind with said peptide; and     -   a comparison sample comprising antibodies which can specifically         bind to said peptide;         wherein said polypeptide, reagent, biological reference sample,         and comparison sample are present in an amount sufficient to         perform said detection.

Another diagnostic kit preferably contemplated is a kit for the detection of the presence or absence of polypeptides indicative of Streptococcus suis strain, comprising:

-   -   an antibody according to the invention;     -   a reagent to detect polypeptide-antibody immune complex;     -   a biological reference sample polypeptides that immunologically         bind with said antibody; and     -   a comparison sample comprising polypeptides which can         specifically bind to said peptide;         wherein said antibody, reagent, biological reference sample, and         comparison sample are present in an amount sufficient to perform         said detection.

EXAMPLES

The present invention will be more readily understood by referring to the following examples. These examples are illustrative of the wide range of applicability of the present invention and are not intended to limit its scope. Modifications and variations can be made therein without departing from the spirit and scope of the invention. Although any methods and materials similar or equivalent to those described herein can be used in the practice for testing of the present invention, preferred methods and materials are described hereinafter.

Example 1 Identification of a Surface Protein of Streptococcus suis and Evaluation of its Immunogenic and Protective Capacity in Pigs

A new Streptococcus suis surface protein reacting with a convalescent serum from pigs clinically infected by S. suis type 2 was identified. The apparent 110 kDa protein designated SP1 exhibits typical features of membrane-anchored surface proteins of Gram-positive bacteria such as a signal sequence and a LPVTG (SEQ ID NO:10) membrane anchor motif. Moreover, a conserved avirulence domain that often found in plant pathogens has been detected. Electron microscopy using a SP1-specific antiserum has confirmed the surface location of SP1 protein on S. suis. The SP1-specific antibody reacts with the cell lysates of most S. suis serotypes and type 2 isolates in immunoblots, demonstrating its high conservation in S. suis species. Immunization of piglets with the recombinant SP1 by intramuscular route elicits a significant total immunoglobulin G (IgG) antibody response. However, the antibody response is not reflected in protection of pigs that are intratracheally challenged with a virulent strain in our conventional vaccination model.

Materials and Methods

Bacterial strains, phage, plasmids and media. Reference strain S735 of S. suis serotype 2 was used for the genomic library construction. Reference strains of the thirty-three serotypes (types 1 to 31, 33 and 1/2), 26 field strains of serotype 2 from different origin as well as five other Gram-positive organisms are listed in Table 1. Phage Lambda Zap II and Escherichia coli XL1-Blue MRF strain were obtained from a commercial source (Stratagene, La Jolla, Calif.). S. suis were grown in Todd-Hewitt broth (THB, Difco, Detroit, Mich.) or agar plates (Quelab Laboratories, Montreal, Canada) at 37° C. with 5% of CO₂, while other Gram-positive bacteria were grown as recommended by the ATCC catalogue. E. coli was grown in either Luria-Bertani (LB) medium alone or LB medium supplemented with 2 g of maltose/liter at 37° C. Where appropriate, E. coli was grown in the presence of 50 μg of ampicillin/ml and 0.8 mM isopropyl-β-D-thiogalactopyranoside (IPTG). pMal™-p vector (New England BioLabs) was used for generating the MBP-SP1 fusion protein.

Antisera. Convalescent swine sera were collected from pigs clinically infected with S. suis type 2 strain S735. Monospecific anti-SP1 serum was obtained by immunizing New Zealand White rabbits intravenously with 230 μg of purified SP1 emulsified with 0.5 ml of Freud's incomplete adjuvant. The rabbits received two booster injections with the same dose of the SP1 at 2-week intervals and then were bled 10 days after the last booster immunization. Sera were stored at −20° C. until used.

Identification, cloning, and sequencing of the sp1 gene. Chromosomal DNA from S. suis S735 strain was isolated as previously described (33). Purified chromosomal DNA was partially digested with the restriction enzyme EcoRI, and the resulting fragments were electrophoresed in 1% agarose gel. Fragments in the 6- to 10-kb size range were extracted from the gel and ligated to the EcoRI arms of λZAPII vector, and the vector was encapsidated using the Gigapack II packaging extract (Stratagene). The recombinant phages were used to infect E. coli XL1-Blue MRF′, which was then plated onto LB agar. The resulting plaques were lifted onto nitrocellulose membranes (Bio-Rad, Mississauga, Ontario, Canada). The membranes were blocked using Tris-saline buffer (TBS) with 2% skim milk and sequentially incubated with the convalescent swine serum from S. suis serotype 2 infection, peroxidase-conjugated rabbit anti-swine immunoglobulin G (IgG) antisera (Jackson Immuno Research Laboratories, Inc., West Grove, Pa.), and O-phenylenediamine. The positive plaques were purified to homogeneity. The recombinant pBluescript plasmids were excised with ExAssist helper phage (Stratagene) according to the manufacturer's instructions. The sequence of the insert was determined using T3 and T7 promoters as primers in DNA Sequencing Facility, University of Maine (Orono, Me., USA). The nucleotide and amino acid sequences deduced from open reading frames (ORFs) were analyzed using programs available on the internet.

The sequence coding for mature SP1 was amplified from purified chromosomal DNA of strain S735 by PCR primers P1 (5′-ATGGATCCATTGAAGGCCGCTCGGCACAAGAAGTAAAA-3′; SEQ ID NO 13) and P2 (5′-CCAAGTCGACTTATAATTTACGTTTACGTGTA-3′; SEQ ID NO 14), which contained BamHI and Sal I restriction sites, respectively. The PCR was performed with 5 min at 94° C., followed by 30 cycles of 1 min at 94° C., 30 s at 56° C., and 1 min at 72° C. The resulting PCR fragment was cloned into Bam HI and Sal I sites of pMAL-p expression vector. The recombinant plasmid containing the sp1 gene was named pORF3.

Expression and purification of recombinant SP1 protein. The purified plasmid pORF3 was used to transform E. coli XL1-Blue strain by electroporation with Genepulse II apparatus (Bio-Rad) following the manufacturer's recommendations. This recombinant strain was grown in LB medium plus 2 g of glucose/L and 50 μg of ampicillin/ml. For over-expression, the culture was inoculated from an overnight culture with its starting OD₆₀₀ adjusted to 0.1. The culture was incubated with agitation until OD₆₀₀ of approximately 0.8, and then IPTG was added in order to induce production of the MBP-SP1 fusion protein. After 2 hours of the induction, the fusion protein was found in the bacterial periplasm as well as in the cytoplasm. It was decided to use extracts of the bacterial lysates for purification of the SP1 protein.

The fusion protein was purified by affinity chromatography using an amylose resin (New England BioLabs) following the manufacturer's instructions. The E. coli cell pellet was suspended in the affinity column binding buffer (20 mM Tris-HCl, 50 mM NaCl, pH 7.4) and cells were lysed using the French Pressure Cell Press (SLM Instruments, Inc.). After filtration with a 0.45 μm membrane, the supernatant was subjected to the amylose resin. The MBP-SP1 fusion protein was eluted with 1% maltose in the binding buffer and protein-containing fractions were determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The purified fusion protein was cleaved with protease Factor Xa (New England BioLabs) at a concentration of 20 μg/mg protein, and applied to a mono-Q column (Amersham Pharmacia Biotech, Baie d'Urfee, Canada). The recombinant SP1 devoid of MBP carrier was eluted from the column by using a linear NaCl gradient (0 to 0.4 M NaCl in 20 mM Tris-HCl, pH 7.4). The SP1-containing fractions were combined and dialyzed against PBS buffer. The purity of the recombinant SP1 was evaluated by SDS-PAGE, and the concentration of the protein was determined by the Bradford protein assay (Bio-Rad) according to the manufacturer's instructions.

SDS-PAGE and western immunoblotting. SDS-PAGE was performed as described by Laemmli (21). Total cell extract or purified protein was separated on a 10% acrylamide gel and the gel was then stained with Coomassie brilliant blue R250 (Sigma, St. Louis, Mo.). Prestained low molecular mass markers (Bio-Rad) were used to determine the apparent molecular weights of proteins. Alternatively, Western blotting of proteins transferred to nitrocellulose membranes was performed essentially as described by Burnette (5).

Immunoelectron microscopy. S. suis S735 strain was grown in 5 ml of THB overnight, centrifuged, and resuspended in 500 μl of PBS (pH8.0). 20 μl of the bacterial suspension was placed on nickel-formvar grids (INRS, Institut Armand Frappier, Laval, Canada) and allowed to partially air dry. After blocking for 30 min with 10% normal donkey serum in dilution buffer (PBS-1% bovine albumin-1% Tween 20, pH8.0), the grids were soaked in 50 μl of SP1-specific rabbit serum or control rabbit anti-MBP serum (New England BioLabs) diluted 1/25 in the dilution buffer for 2 h at room temperature. The grids were washed three times in PBS-1% Tween20, and then transferred into 50 μl of 12 nm colloidal gold-affinipure donkey anti-rabbit IgG (Jackson ImmunoResearch Laboratories) diluted 1/30 in the dilution buffer and incubated for 1 h at room temperature. After three washes with PBS-1% tween20 and one wash with distilled water, bacteria were stained with 1% phosphotungstic acid and examined with an electron microscope (Philips 201) at an accelerating voltage of 60 kV.

Immunization and protection study. Pigs were used to perform the immunization and protection assay at VIDO (Saskatoon, Canada) in accordance with principles outlined in the “guide to the care and use of experimental animals” of the Canadian Council on Animal Care using a protocol that was approved by the University Committee on Animal Care (37). Three week-old piglets with average weight of 8.23 kg from a herd that is free of S. suis serotype 2 were randomly assigned to two groups of eight. The pigs were injected intramuscularly twice at a 3-week interval with 1 ml of either 100 μg purified SP1 mixed with 30% Emulsigen-Plus (MVP Laboratories, Ralston, Nebr.) adjuvant or 30% Emulsigen-Plus in physiological saline as a control. Eleven days after the second injection, the immunized and control animals were challenged by aerosol of 1 ml (4.6×10⁶ CFU) of a log-phase culture of S. suis virulent strain 166, which has been confirmed to be highly virulent (3). Blood samples were collected prior to each injection, challenge and the end of the experiment for determination of antibody responses. Pigs were monitored daily for clinical signs, body temperature and mortality for ten days after challenge. All pigs were examined postmortem for gross pathology and blood was cultured to detect the presence of S. suis bacteremia.

ELISA. Serum SP1-specific total IgG and IgG isotypes (IgG1 and IgG2) of immunized piglets were determined by enzyme-linked immunosorbent assay (ELISA). Polysorb plates (Nunc-Immunoplates, Rochester, N.Y., USA) were coated overnight at 4° C. with 100 μl per well of the purified recombinant SP1 at a concentration of 0.3 μg/ml in carbonate buffer. After three washes with PBS containing 0.05% Tween20 (PBST), the plates were blocked with 5% skim milk in PBST for 1 h at 37° C. For determination of total IgG, swine sera from the control and vaccine groups were diluted 1/5000 in PBST and added to appropriate wells in duplicate at 100 μl per well. After incubation for 1 h at 37° C. and washing three times, bound antibodies were detected by incubation for 1 h at 37° C. with peroxidase-conjugated goat anti-swine IgG(H+L) antisera (Jackson Immuno Research Laboratories). For IgG1 and IgG2 detection, 1/500 diluted swine sera from vaccine group were added at 100 μl per well. Mouse antiporcine IgG1 or IgG2 (Serotec, Kidlington, Oxford, UK) was used as the primary antibody, and peroxidase-conjugated goat anti-mouse IgG(H+L) (Serotec) was used as the secondary antibody. The plates were developed with TMB substrate (Zymed, S. San Francisco, USA). Absorbance was measured at 450 nm in an ELISA reader (Power Wave 340, Bio-Tek Instruments, Inc.). Results were expressed as the means±S.D. Statistical significance was determined by Student's t test.

Nucleotide sequence accession number. The sequence of the gene encoding SP1 protein of S. suis is shown in FIG. 2 and has been assigned GenBank accession number AY864331.

Results

Identification of sp1 gene. The S. suis chromosomal library was constructed from the S. suis S735 strain in λZAPII and screened using convalescent swine sera from S. suis serotype 2 infected animals. One clone, which expressed a protein with an apparent molecular weight (MW) of 110 kDa that was strongly reactive against the convalescent swine scrum, was selected for further characterization. The recombinant pBluescript plasmid, designated pSS735, was excised from the bacteriophage arms, and its schematic organization is presented in FIG. 1. DNA sequence analysis of the 6057-bp insert of the pSS735 revealed four ORFs. This gene cluster was found in the partially sequenced genomes of S. suis Canadian strain 89/1591 (NZ_AAFA00000000) and European strain P1/7 (NC_004549) with the same organization. The deduced amino acid sequences of both ORF1 and ORF2 showed identities ranging from 50-80% with a glycosyl transferase, and ORF4 showed identities ranging from 50-75% with a catabolite control protein A from many bacterial species, most of them belong to the genus Streptococcus. The ORF3 encodes a 670 amino acid protein, designed SP1, with a predicted p1 of 6.0 and a calculated molecular mass of 74.8 kDa. Comparison of the amino acid sequence of SP1 with those in available databases revealed no significant homology with other proteins. Subcloning analysis of the sp1 sequence in pMal-p vector revealed that the SP1 strongly reacted with the convalescent swine serum, demonstrating that SP1 is the immunogenic protein.

SP1 is a novel C-terminal-anchored surface protein of S. suis. The 2010 bp of sp1 gene starts with an ATG codon which is preceded by putative Shine-Dalgarno sequence (GAAAGGA) 10 bp upstream of the start codon and terminates with a TAA codon (FIG. 2). Analysis of the predicted SP1 amino acid sequence revealed a hydrophobic core of 15 amino acids at the N-terminus and a putative signal-peptidase cleavage site between Ala²⁹ and Gln³⁰. Ten repeats of 27-amino-acid sequence with a strong consensus pattern, separated by 3-amino-acid residue spacers, were detected within the carboxyl half of the protein. Immediately C-terminal from the repeat region is a cell wall-associated region, which spans 49-amino-acid residues and is characterized by a high percentage of threonine residues (20.4%). This threonine-rich region is immediately followed by an LPVTG (SEQ ID NO:10) consensus motif typical of membrane-anchored surface proteins of many Gram-positive bacteria. Beginning four amino acids C-terminal from the membrane anchor motif, a second hydrophobic segment of 16 amino acids was identified, which is followed by four positive charged amino acid residues at the C-terminal end of the protein (FIG. 2).

Analysis of the amino acid composition revealed a region of absence of aromatic residues between Glu²⁷² and Thr⁶³⁰, which spans all of the repeat sequences. Furthermore, a conserved domain search using BLAST identified an avirulence domain in Lys³¹⁹ to Val⁶⁰¹ region, which exhibits similarity with AvrXa7 avirulence factor from the plant pathogen Xanthomonas oryzae pv. oryzae (41) with 20% identity (FIG. 3). If conservative amino acid substitutions are taken into consideration, the similarity is 48%.

Production of the recombinant SP1. The sequence coding for mature SP1 protein was amplified by PCR and ligated into the IPTG-inducible pMAL-p vector. The resulting recombinant plasmid was expressed in E. coli XL1-Blue strain. As shown in FIG. 4A, induction of the E. coli recombinants harboring the malE-sp1 fusion gene led to the expression of an approximately 150 kDa of MBP-SP1 fusion protein (lane 2) which was absent in the non-induced E. coli cells (lane 1). The fusion protein was mostly found in the cytoplasm of the E. coli cells (lane 3). Interestingly, a truncated MBP-SP1 fusion protein in which the repeating region characterized by absence of aromatic substitutions was deleted was completely transported into the periplasmic space (data not shown), suggesting that this region somehow interfered with MBP localization.

The fusion protein was purified by using affinity matrix amylose column and eluting with maltose, and showed a single protein band of approximate 150 kDa on SDS-PAGE (lane 4). The purified fusion protein was proteolytically cleaved with Factor Xa, yielding the apparent 110 kDa of mature SP1 and the expected 45 kDa of MBP tag (lane 5). The mature SP1 devoid of MBP was obtained by subsequent purification with ion-exchange chromatography, with a purity>95% estimated by SDS-PAGE (lane 6). Both the MBP-SP1 fusion protein and the purified recombinant SP1 demonstrated specific reactivity in a western blot to the convalescent swine serum used for the initial screening of the genomic library (FIG. 4B). Identity of the purified SP1 was confirmed by N-terminal protein sequencing. The protein concentration was measured with Bradford protein assay and adjusted to 1 mg/ml.

Cell surface expression of SP1 in S. suis. To confirm the location of SP1 on the surface of S. suis cells, immunoelectron microscopy was conducted by using a monospecific polyclonal anti-SP1 antibody, R44. Immunogold particles were found to be evenly distributed on the surface of the S. suis S735 strain. This indicates that SP1 protein is homogeneously expressed on the cellular surface. Rabbit anti-MBP serum was used as control and did not show any labeling (FIG. 5).

Distribution of the SP1 among S. suis. To evaluate the conservation of SP1 among reference strains of deferent serotypes of S. suis and serotype 2 field strains, whole cell preparations of the bacteria were applied to western blots and detected by SP-specific antibody R44. As shown in Table 1, except for strains of serotypes 13, 16, 20, 22 and 24, R44 reacted with other 28 S. suis serotypes, while 25 of 26 tested type 2 isolates from different geographic origins reacted with the R44 antibody. Five strains from other species of Streptococci were used to verify the specificity of SP1 and no SP1 protein were detected.

Immunogenicity of SP1 and protection of pigs against challenge with S. suis. Groups of 8 piglets were immunized twice intramuscularly with either 100 μg of purified recombinant SP1 emulsified with the adjuvant or adjuvant only. Immunization of pigs with SP1 triggered an antigen-specific response (FIG. 6A). Analysis of corresponding sera obtained from the control animals and the animals before immunization clearly indicated that there was no SP1-specific antibody, since only background ELISA values were recorded. Only two weeks after the first injection, SP1 elicited a significant IgG response that was obviously enhanced by the boost immunization. Assessment of IgG isotypes demonstrated that sera from immunized pigs contained both IgG1 and IgG2 antibodies (FIG. 6B). However, IgG1 response dominated over IgG2, suggesting that vaccination with SP1 mainly induced the Th2-like immune response. Aerosol challenge of the pigs with S. suis 166 strain resulted in steady increases of clinical score starting from day 2 after the challenge and there was no significant effect of the vaccination. As summarized in Table 2, although fewer pigs suffered arthritis in the vaccinated group than in the control group, both groups showed similar symptoms after challenge. Three pigs from each group died or were euthanized due to high clinical scores prior to the end of the experiment. S. suis bacteremia was found in all dead pigs and was not detected in the surviving pigs.

Discussion

First immunization of pigs elicited rapid SP1-specific humoral antibody response that can be significantly boosted by a subsequent injection. However, the antibody to SP1 did not confer immunity against an heterologous challenge using S. suis strain 166. This discrepancy between antibody response and protection have been reported in some other surface antigens of Gram-positive bacteria, such as streptococcal fibronectin binding protein (Sfb1) (26), pneumococcal surface protein A (PspA) (27), group B polysaccharide (25) and M-like protein (SeM) of Streptococcus equi (34). The reason why antibodies against SP1 were not protective against the challenge by S. suis 166 is unclear. In a phagocytic killing study, presence of pooled serum from the SP1-immunized pigs did not promote S. suis killing by porcine neutrophils, suggesting that the antibodies are lacking opsonophagocytic function. Host protection against infection caused by S. suis, a highly encapsulated microorganism, is mediated primarily by phagocytosis (32). Therefore, total IgG levels generated in the Applicant's conventional vaccination model may not adequately reflect the presence of protective antibodies that are capable of triggering leukocyte effector functions. To further illustrate the immune response types trigged by SP1, IgG isotypes in immunized sera were assessed. IgG1 levels were consistently higher then IgG2 levels suggesting the induction of Th2-like responses. Although the concept of “Th1/Th2” balance is not yet well documented in pigs as in some other species, recent evidence showed that porcine IgG2 had greater complement activating ability than did IgG1 (6).

Emulsigen-Plus was used as an adjuvant in this study, because it was believed to be capable of creating an antigen depot at the site of inoculation from which the antigen is slowly released and thus providing prolonged stimulation to the immune system (23, 37). However, recent evidence showed that vaccine formulated with Emulsigen alone triggered predominantly an IgG1 response but very weak Th1-type immune response (19, 28). Evidence from vaccination using surface antigens of other Gram-positive bacteria has demonstrated that efficiency of opsonophagocytosis can be dramatically enhanced by using Th1-directing adjuvants, such as CpG and interleukin-12 (IL-12) (4, 22, 24). These adjuvants promote a Th1-type immune response characterized by enhanced production of opsonizing antibodies, specially IgG2 isotype. Furthermore, the enhanced antibodymediated opsonization was clearly reflected in protection (2, 40).

In conclusion, SP1 is a novel C-terminal-anchored surface protein of S. suis, as demonstrated by analysis of the molecular features and electron microscopy. Vaccination with the recombinant SP1 elicited significant humoral antibody response in piglets, along with the fact that convalescent swine sera present high titers of antibody against this protein, suggesting that SP1 is an exposed antigen of S. suis. Taken together with its wide distribution in different S. suis serotypes, these findings made the SP1 a candidate for consideration in the development of a subunit vaccine. The potential of SP1 as a vaccine candidate will be demonstrated in the following Examples.

Example 2 Recombinant SP1 Protects Mice Against S. suis Challenge Infection

This study is to evaluate whether the SP1 recombinant protein is protective as a subunit vaccine candidate in a mouse model with a modified immunization route and adjuvant.

EXPERIMENTAL PROCEDURE: Mice (CD1) were randomly assigned to two groups of ten, and immunized subcutaneously twice at 2-week interval with either 20 μg of purified SP1 mixed with 20 μg of Quil A as a adjuvant or 20 μg of Quil A only as a control (Table 1). Ten days after the second vaccination, the animals were challenged i.p. with 1×10⁸ CFU of a S. suis virulent strain (31533). The mice were monitored twice a day for clinical signs and mortality until day 14 after the infection. Blood samples were collected prior to each vaccination and challenge for determining antibody responses.

RESULTS: Vaccination with SP1 elicited significant humoral IgG responses in mice after primary immunization (mean titre 3×10⁴) and a booster injection significantly increased the antibody titre (1.8×10⁶). In contrast, the SP1-specific IgG in sera of control group was at undetectable level (FIG. 1). Furthermore, all of four IgG subclasses were induced in SP1-immunized mice, with the IgG2a titre being the highest (1.75×10⁶) followed by IgG1 (1.2×10⁶), IgG2b (7.25×10⁵) and IgG3 (3.7×10⁴) (FIG. 2). Specificity of SP1-induced antibodies was demonstrated by Western blot in which pooled sera collected from SP1-immunized mice can recognize the purified SP1 and the SP1 protein in S. suis S735 and 31533 cell preparations.

Sixteen hours after administering the challenge infection, all mice in control group started to exhibit clinical signs (septicemia), such as the ruffled hair coat (suggesting fever) and slow response to stimuli. Starting from day 4 after the challenge, 8 of 10 mice in this group successively developed severe central nervous system symptoms (meningitis) such as running in circles and opisthotonos. All of the 8 ill mice died, or had to be euthanized due to the severity of the condition. In contrast, except for 6 of 10 mice in SP1-vaccinated group had transient clinical signs such as slight rough hair and reluctant to move during 16-40 hours after the challenge, all mice in this group remained healthy during the observation period (FIGS. 3 and 4).

DISCUSSION AND CONCLUSION: The difference in protection observed in mouse and pig models is explained by well-balanced IgG subclass levels evoked in the mouse vaccination model, especially the extremely high IgG2a titre. Among murine antibody isotypes, IgG2a has been shown to be the most effective at activating opsonophagocytic function of leukocytes (2, 42, 43)). Furthermore, S. suis, an encapsulated bacterial, is most effectively eliminated by opsonophagocytosis. Thus, it is likely that predominant IgG2 production contributed most to the observed protection. Nevertheless, these data indicate that immunization of mice with SP1 by using a Th1 inducing adjuvant, such as Quil A, can induce an efficient antigen-specific response, and protect mice against challenge infection with a lethal dose of a virulent S. suis strain and result in complete protection from S. suis death (FIG. 4).

Example 3 Identification of a Novel Gene Encoding a Streptococcus suis Protein with IgG-Binding Activity and Protective Capacity

In the Applicant's continued effort to understand the pathogenic mechanism of S. suis and search for its protein(s) that may be useful in the development of a reliable diagnostic reagent or vaccine, a new protein which exhibits IgG-binding activity was identified from a virulent strain of S. suis serotype 2. This apparent 58-kDa protein designed SP2 contains a 23 amino acids cleavable N-terminal signal sequence and a lysine M motif near the N-terminus, and six identical repeats of 13 amino acids each within the C-terminal part. SP2 is highly conserved among different S. suis serotypes as demonstrated by PCR amplification of the SP2 gene. Recombinant SP2 strongly reacted with a convalescent swine serum collected from pigs clinically infected by S. suis type 2. Immunization of mice with the purified recombinant SP2 elicits a significant antibody response that conferred a partial protection against challenge infection with a virulent S. suis strain.

These results show that SP2 is a potential diagnostic agent and vaccine candidate for S. suis infection.

Experimental Procedures and Results

Identification of SP2 Gene

A positive phage which reacted by non immune mechanism with different classes and species of Ig (Pig IgG, Human IgG and IgA) was identified by screening the constructed S. suis serotype 2 genomic library. Sequence of the DNA insert revealed a 6.3 kb insert which contains three ORFs coding for dehydrogenases, SP2 and dextran glycosidases (44), respectively (FIG. 12). This gene cluster was found in the partially sequenced genomes of S. suis Canadian strain 89/1591 (NZ_AAFA00000000) and European strain P1/7 (NC_004549) with the same organization. The SP2 amino acid sequence presented similarities with some streptococcal proteins usually exhibiting Ig-binding activity. An identity of 45% in a 395-amino acid stretch was observed with a Conserved hypothetical protein of Streptococcus pneumoniae (AAL00677). Other homologies were found with a putative 42 kDa protein of Streptococcus pyogenes (45% identity over 388-amino acid stretch) (AAK33481) and with a group B streptococcal surface immunogenic protein (40% identity over 434-amino acid stretch) (60) (AAG 18474).

Characterization of SP2 Protein

The 1158 bp SP2 gene encodes a 386-aa SP2 protein, with a theoretical p1 of 4.40 and molecular mass of 42.5 kDa. This protein was rich in valine (15%), glutamic acid (10%), and alanine (9%). Charge distribution analysis of SP2 revealed one positive charge cluster (K²-K²⁶) at the N-terminus and one negative charge cluster (D¹⁶⁸-E²⁴²) in middle of the protein (FIG. 13). The positive charge cluster was followed by a putative signal sequence of 23 amino acids. The amino acid sequence of SP2 contains a LysM (lysine) motif at positions 71 through 109. This LysM domain is found in a variety of enzymes involved in bacterial cell wall degradation and has a general peptidoglycan binding function, suggesting that SP2 may be a surface protein of S. suis. Thus, the N-terminal constitution of SP2 outlined a possibility that the positive charge cluster remained in the cytoplasm functions as a temporary stop and helps in formation of mature SP2 by cleaving the signal sequence and in location of SP2 on the bacterial surface via binding of LysM domain to peptidoglycan. Furthermore, six identical repeating sequences of 13 amino acids were identified in the middle part of SP2 (FIG. 13).

Distribution of SP2 Gene in Different S. suis Serotypes

To evaluate the conservation level of SP2, PCR were performed using primers covering the full-length SP2 gene. PCR was performed with an initial denaturing at 94° C. for 5 min followed by 30-cycles of 1 min at 94° C., 1 min at 52° C. and 2 min at 72° C., and a final elongation period of 10 min at 72° C.

The forward and reverse primers used for SP2 distribution in different serotypes were respectively:

(5′-TTTAAAAGAACGGTTGAAGGC-3′;       SEQ ID NO: 15) and 5′-GCATAAGCTGCCACTTGATCT-3′;       SEQ ID NO: 16).

SP2 gene was amplified from 31 of the 33 serotype reference strains with some size variations (FIG. 14). Sequence analysis of selected variant fragments suggested that the number of repeats in the SP2 gene is responsible for the size variations.

Production and Purification of Recombinant SP2

The gene coding for mature SP2 was generated by PCR from S. suis S735 chromosome and subcloned to a pET32+vector (New England BioLabs). The construct was used to transform E. coli DE3 strain by electroporation with Genepulse II apparatus (Bio-Rad) following the manufacturer's recommendations. For over-expression, the culture was inoculated from an overnight culture with its starting OD₆₀₀ adjusted to 0.1. The culture was incubated with agitation until OD₆₀₀ of approximately 0.8, and then IPTG (0.5 mM) was added in order to induce production of the Trx-His-SP2 fusion protein. After 2 hours of the induction, bacterial cytoplasm were prepared and used for purification of the SP2 protein.

The Trx-His-SP2 fusion protein was purified from the cytoplasm by affinity chromatography using Ni+ column (Amersham Pharmacia Biotech, Baie d'Urfee, Canada). The cytoplasm was filtered with a 0.45 μm membrane and subjected to the column. The fusion protein was eluted with 500 mM imidazole in binding buffer and protein-containing fractions were determined by SDS-PAGE. The purified fusion protein was cleaved by 0.001% (w/w) of enterokinase (New England BioLabs), yielding an apparent 58 kDa SP2 and the expected 20 kDa Trx-His tag (FIG. 15), and then applied to a mono-Q column (Amersham Pharmacia Biotech, Baie d'Urfee, Canada). The recombinant SP2 devoid of Trx-His tag was obtained from elution of the column by using a linear NaCl gradient, with an estimated purity greater than 95% as visualized by SDS-PAGE (FIG. 15). The protein concentration was determined by the Bio-Rad protein assay kit (Bio-Rad) according to the manufacturer's instructions. Identity of the purified SP2 was confirmed by N-terminal protein sequencing.

SP2 is an Immunogenic Protein of S. suis and Exhibits IgG-Binding Activity

SP2-specific antibody was generated by immunizing New Zealand White rabbits intramuscularly with 100 μg of recombinant SP2 protein emulsified with 0.5 ml of Freud's incomplete adjuvant. The rabbits received two booster injections with the same dose of the SP2 at 2-week intervals and then were bled 10 days after the last booster immunization. The SP2 specific antibody conversely recognized SP2 in S. suis cell preparation in a western blot (FIG. 16a). Moreover, recombinant SP2 reacted with a convalescent swine serum (FIG. 16b), demonstrating that the anti-SP2 antibody exists in the serum of pigs clinically infected by S. suis.

The binding activities of the recombinant SP2 to human and pig IgG were demonstrated in FIGS. 16c and 16d.

Recombinant SP2 Partially Protects Mice Against S. Suis Challenge Infection

Mice (CD1) were randomly assigned to two groups of eleven (vaccine group) and ten (control), and immunized subcutaneously twice at 2-week interval with either 50 μg of purified SP2 mixed with 20 μg of Quil A as a Th1 inducing adjuvant or 20 μg of Quil A only as a control. Ten days after the second vaccination, the animals were challenged i.p. with 1×10⁸ CFU of a S. suis virulent strain (31533). The mice were monitored twice a day for clinical signs and mortality until day 14 after the infection. Blood samples were collected prior to each vaccination and challenge for determining antibody responses.

Vaccination with SP2 elicited significant humoral IgG responses in mice. In contrast, the SP2-specific IgG in sera of control group was at undetectable level (FIG. 17). Both groups showed clinical signs of septicemia and meningitis, however, the clinical scores in SP2 vaccination group are lighter than in the control group (FIG. 18). 4 of 11 mice in SP2 vaccination group died or had to be euthanized due to the severity of the condition (survivor rate=64%). In contrast, 8 of 10 mice in control group died (survivor rate=20%) (FIG. 19). These results show that SP2 protects mice against S. suis challenge infection.

Conclusion

SP2 is a new described S. suis immunogenic protein which shares little identity with other known sequences. Convalescent swine sera present antibody against this protein, demonstrating that SP2 is a potent antigen that is expressed during S. suis infection. These findings, along with its wide distribution in different S. suis serotypes, make the SP2 a candidate for consideration in the development of a diagnostic reagent. Since vaccination of mice with recombinant SP2 resulted in protection, it is thus clear that SP2 is a potential vaccine candidate against S. suis infection.

Example 4 Effect of Immunization of Piglets with Experimental Streptococcus Suis Vaccine

This study evaluates the protective effect of recombinant Sao protein on S. suis serotype 2 challenge infection in piglets.

Materials and Methods

Animals, Allocation to Treatment and Exclusion Criteria:

A total of 24 crossbred piglets from S. suis disease-free herd (H & M Fast Farms Inc.) without any previous vaccination against S. suis were used. The pigs were kept under commercial conditions at the herd of origin from birth until they were weaned at an average weight of 7.79 kg at 23.5 days of age. Pigs were housed with controlled temperature (27 to 30° C.) and ventilation, on vinyl-covered metal flooring, and were provided with water via nipple waterers and had free access to commercially-prepared, nutritionally balanced, antibiotic-free feed. A veterinarian examined the pigs prior to the beginning of the study. All were healthy. At weaning, the piglets were randomly assigned to two groups, balanced by body weight.

Group 1: 200 μg Sao and 400 μg Quil A in 1 mL Saline

Group 2: 400 μg Quil A in 1 mL Saline (control)

Any animals that receive an unintended treatment or succumb to an unrelated disease will be excluded from analysis.

Vaccination and Challenge:

All pigs were vaccinated IM with 1 ml twice at 2-week interval. Blood samples were collected before each injection and challenge. There were no adverse events as a result of these treatments.

Two weeks after the second vaccination, the pigs were anesthetized with halothane and challenged by aerosol of 1 ml of a suspension of S. suis 166. The bacteria were from a log-phase culture grown in filter sterilized Todd-Hewitt Yeast Broth to an OD₆₂₀ of 0.8 and diluted 1:100 in saline (0.85% NaCl). The bacterial concentration administered to pigs was later measured to be 6.8×10⁶ CFU/ml.

Clinical Observations:

A veterinarian or trained animal care technician clinically evaluated the pigs once daily and measured body temperatures during assignment of clinical scores each morning for ten days after challenge. A daily clinical score (from 0 to 4) was derived as the sum of attitude and locomotion scores for each animal based upon signs of nervous, musculoskeletal or respiratory disease as follows:

Attitude:

-   0=Normal attitude and response to stimuli -   1=Inactive and slow to respond; oculo-nasal secretions -   2=Only responsive to repeated stimuli, apathetic -   3=Recumbent, nonresponsive, unaware of surroundings -   4=Dead     Locomotion: -   0=Normal gait and posture -   1=Slight in coordination, lameness and/or joint swelling but rises     without assistance -   2=Clearly uncoordinated or lame but stands without assistance -   3=Severe lameness, severe ataxia, does not remain standing -   4=Dead

Pigs having a clinical score greater than 2 on either scale were euthanized by lethal injection. Pigs with rectal temperatures equal to or greater than 40.6° C. and a clinical score greater than 0, as well as those pigs that were dead, were recorded as sick on that day. Pigs that died or were euthanized prior to the end of the experiment on day 9 were recorded as dead for evaluation of the effect of treatment on mortality rate. All individuals making judgements about animals, evaluating clinical signs of disease, or performing laboratory assays were blind to the identity of the treatment.

Haemotologic Condition:

A heparin-treated blood sample was obtained by venipuncture for detection of S. suis bacteremia (by culture on days 0 and 3 after challenge and postmortem).

Antibody Titre:

Titers of Sao-specific total IgG and IgG subclasses (IgG1 and IgG2) in sera were determined by ELISA. The serum dilution that resulted in an OD450 reading of 0.1 after background subtration was considered the titer of this serum.

Necropsy:

All pigs were examined postmortem and the following tissues were cultured for bacteria: cerebellum swab, tracheobronchial lymph node, a joint swab (an affected joint if lesions are present; otherwise a stifle joint), and blood. The number of S. suis bacteria that were recovered was recorded on an ordinal scale from 0 to 4 (approximating the log₁₀ number of colonies). In addition, the extent (percentage) of pulmonary involvement was estimated by visual examination.

Statistical Analysis

The significance of differences between groups in nominal data (mortality, presence or absence of S. suis in the tissues, days sick or well) was determined using contingency table analysis and Likelihood-Ratio Fisher Exact Test. The significance of differences between groups in ordinal data (clinical score) was transformed by ranking and determined by t-test. The significance of differences between groups in survival curves was determined by survival analysis using the logrank test (equivalent to the Mantel-Haenszel test). The significance of differences among groups in continuous data (length of survival after challenge, body temperature, log, CFU/ml of blood) was determined using t-test (after appropriate transformation to normality as required).

Results

Excluded Animals:

One pig was humanely killed on day 5 after the challenge because of persistent; worsening prolapsed rectum. This pig will be excluded from analysis.

Clinical Observations:

-   1. Response to immunisation: There were no unusual reactions     attributable to vaccination. -   2. Body temperature: The body temperature data as analysed by     t-test, showed no significant difference between the two group     (p>0.05). Generally the vaccinated pigs tended to have lower     temperatures (FIG. 20) -   3. Clinical disease: The “clinical score” is a measure of the amount     of disease and incorporates both mortality and morbidity. The two     groups were compared using Mann-Whitney analysis of an effect of     vaccine on clinical score, and the clinical disease in vaccinated     group was significantly less than that in control (p=0.024) (FIG.     21). -   4. Survival of pigs after S. suis challenge: The survival rate is     82% in vaccination group and 42% in control group, respectively.     Comparison of survival curves using the two data sets, shows that     the survival time of vaccinated pigs was significantly longer than     that of control (p=0.048) (FIG. 22).     Bacteriology -   1. Bacteremia: Bacteria in the blood of piglets were not detected     (ND) before challenge. The bacteremia pigs after challenge and     postmortem were not significant different between the two groups.     However, the vaccinated pigs had less bacteremia (table 3). -   2. Infection postmortem: Microbiologic culture of samples from the     brain, tracheobronchial lymph node, and joint of all of the pigs     that were challenged was done to monitor the level of infection.     Number of tissues from that bacteria with colonial morphology     typical of the challenge strain were recovered was shown in table 4.     The Wilcoxon Rank Sum test for the effect of vaccinated group on the     median bacteriology score (median of the sum of scores for all     tissues of each pig) showed that this difference was significant     (p=0.007).     Pathology (Post-Mortem)

Pathologic lesions of arthritis or pneumonia were detected in only 6 pigs (2 in vaccinated group and 4 in control). Other dead or euthanized pigs had no gross pathologic signs. One of characterizations of S. suis infection is that acute infection can be fatal without appreciable gross signs of pathology. The tracheobronchial lymph node was enlarged. There was a trace of fibrin on the mesentery, indicating a mild peritonitis. There was evidence of arthritis in both stifles, in which there was a small amount of purulent material, and in the left shoulder, where there was a trace of purulent exudate.

Antibody Response

Immunization of pigs with Sao in combination with Quil A elicited significant humoral IgG responses after primary immunization and a booster injection significantly enhanced the antibody titre (FIG. 23). Furthermore, while both IgG1 and IgG2 subclasses were induced, IgG2 titer dominated over IgG2 as measured in the sera 2 weeks after the second vaccination (FIG. 24).

Summary and Discussion

The vaccine was shown to be safe since pigs that were vaccinated twice did not have any adverse reaction. Immunization of pigs with Sao in combination with Quil A elicited significant IgG titres with a dominant IgG2 production, suggesting a predominant Th1-type immune response. Aerosol challenge of pigs resulted in disease with an overall mortality rate of approximately 58% in controls. The survival of vaccinated pigs after challenge was significantly better than controls (p<0.05). Some pigs in each group became ill after challenge, and there was significantly less disease (lower clinical score) in the vaccinated pigs. Vaccination had no significant effect on the occurrence of gross pathology post-mortem; however acute streptococcal septicaemia can be fatal without appreciable gross signs of pathology. Less S. suis bacteria were recovered from vaccinated pigs than control pigs post mortem (p<0.01).

Example 5 Immunization of Mice and Piglets with Fragment SP1A

Immunization of Mice

Three groups of 10 mice were immunized two times (Day 1 and Day 17) via i.p. with 40 μg of purified SP1A-maltose-binding protein (MBP) fusion protein, 20 μg of MBP or only PBS, using Freund Incomplete as an adjuvant. The sera were obtained before each immunization or 10 days after the second injection, and were 1:5000 diluted for ELISA assay. (See Table 5)

Immunization of Pigs

Three groups of 3 pigs were immunized two times (Day 1 and Day 17) via i.m. with 200 μg of purified SP1A-MBP fusion protein, 100 μg of MBP or only PBS, using Emulsigen as an adjuvant. The sera were obtained before each immunization or 10 days after the second injection, and were 1:5000 diluted for ELISA assay. (See Table 6)

TABLE 1 Distributions of SP1 in S. suis reference strains, isolates of serotype 2 and other organisms detected by SP1-specific antibody R44 in Western blots. S. suis serotype S. suis isolate (reference strain) Origin SP1 of serotype 2 Origin SP1  1 (5428) The Netherlands + 89-999 Canada + ½ (2651) The Netherlands + 90-1330 Canada +  2 (NCTC 10234) The Netherlands + 95-8242 Canada +  3 (4961) Denmark + Man 25 Canada +  4 (6407) Denmark + Man 50 Canada +  5 (11538) Denmark + Man 63 Canada +  6 (2524) Denmark + AAH4 USA +  7 (8074) Denmark + AAH5 USA +  8 (14636) Denmark + AAH6 USA +  9 (22083) Denmark + 1309 USA + 10 (4417) Denmark + 88-5955 USA + 11 (12814) Denmark + 95-13626 USA + 12 (8830) Denmark + 95-16426 USA + 13 (10581) Denmark − 95-7220 USA + 14 (13730) The Netherlands + 97-8506 USA + 15 (NCTC 1046) The Netherlands + SX-332 USA + 16 (2726) Denmark − JL 590 Mexico + 17 (93A) Canada + 166 France + 18 (NT77) Canada + 96-39247 France + 19 (42A) Canada + 96-49808 France + 20 (86-5192) USA − 96-53405 France + 21 (14A) Canada + Italie 57 Italy + 22 (88-1861) Canada − Italie 68 Italy + 23 (89-2479) Canada + Italie 69 Italy − 24 (88-5299A) Canada − Italie 228 Italy + 25 (89-3576-3) Canada + S735^(a) The Netherlands + 26 (89-4109-1) Canada + 27 (89-5259) Canada + 28 (89-590) Canada + 29 (92-1191) Canada + 30 (92-1400) Canada + 31 (92-4172) Canada + 33 (EA1832.92) Canada + Organnism Strain SP1 1 2 S. bovis ATCC 9809 − 3 4 S. equisimilis ATCC 9542 − 5 6 S. intestinalis ATTC 43492 − 7 8 S. pyogenes ATCC 14289 − 9 10 S. uberis ATCC 6580 − ^(a)Strain used as reference in this work.

TABLE 2 Protection of pigs following challenge with S. suis strain 166 Arthritic Bacteremic Surviving Groups (n = 8) pigs pigs pigs Emulsigen-Plus (Control) 6 3 5 Emulsigen-Plus + SP1 4 3 5

TABLE 3 Level of S. suis bacteremia. Groups Sao + Quil-A Quil-A Significance (p) Before challenge ND (12) ND (12) N/A 3 days after 1/11 2/12 0.6 challenge Postmorterm 1/11 4/9  0.13

TABLE 4 Level of infection postmortem. Lymph Median bacteriology Groups Brain node Joint score Sao + Quil-A  2/11 6/11 2/11 1.0 Quil-A 10/12 8/12 4/12 4.5

TABLE 5 SP1A-specific IgG response in mouse sera (A450 nm) Group SP1A-MBP MBP PBS Before Immunization 0.006 0.016 0.0 After 1^(st) Immunization 2.809 0.015 0.005 After 2^(nd) Immunization 3.153 0.015 0.004

TABLE 6 SP1A-specific IgG response in pigs (A450 nm) Group SP1A-MBP MBP PBS Before Immunization 0.024 0.018 0.024 After 1^(st) Immunization 0.254 0.026 0.015 After 2^(nd) Immunization 0.501 0.047 0.033

REFERENCES

-   1. Arends, J. P., and H. C. Zanen. 1988. Meningitis caused by     Streptococcus suis in humans. Rev Infect Dis 10:131-7. -   2. Arulanandam, B. P., J. M. Lynch, D. E. Briles, S. Hollingshead,     and D. W. Metzger. 2001. Intranasal vaccination with pneumococcal     surface protein A and interleukin-12 augments antibody-mediated     opsonization and protective immunity against Streptococcus     pneumoniae infection. Infect Immun 69:6718-24. -   3. Berthelot-Herault, F., R. Cariolet, A. Labbe, M.     Gottschalk, J. Y. Cardinal, and M. Kobisch. 2001. Experimental     infection of specific pathogen free piglets with French strains of     Streptococcus suis capsular type 2. Can J Vet Res 65:196-200. -   4. Buchanan, R. M., D. E. Briles, B. P. Arulanandam, M. A.     Westerink, R. H. Raeder, and D. W. Metzger. 2001. IL-12-mediated     increases in protection elicited by pneumococcal and meningococcal     conjugate vaccines. Vaccine 19:2020-8. -   5. Burnette, W. N. 1981. “Western blotting”: electrophoretic     transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels     to unmodified nitrocellulose and radiographic detection with     antibody and radioiodinated protein A. Anal Biochem 112:195-203. -   6. Crawley, A., and B. N. Wilkie. 2003. Porcine Ig isotypes:     function and molecular characteristics. Vaccine 21:2911-22. -   7. Elliott, S. D., F. Clifton-Hadley, and J. Tai. 1980.     Streptococcal infection in young pigs. V. An immunogenic     polysaccharide from Streptococcus suis type 2 with particular     reference to vaccination against streptococcal meningitis in pigs. J     Hyg (Lond) 85:275-85. -   8. Galina, L., U. Vecht, H. J. Wisselink, and C. Pijoan. 1996.     Prevalence of various phenotypes of Streptococcus suis isolated from     swine in the U.S.A. based on the presence of muraminidase-released     protein and extracellular factor. Can J Vet Res 60:72-4. -   9. Gottschalk, M., R. Higgins, M. Jacques, M. Beaudoin, and J.     Henrichsen. 1991. Characterization of six new capsular types (23     through 28) of Streptococcus suis. J Clin Microbiol 29:2590-4. -   10. Gottschalk, M., R. Higgins, M. Jacques, M. Beaudoin, and J.     Henrichsen. 1991. Isolation and characterization of Streptococcus     suis capsular types 9-22. J Vet Diagn Invest 3:60-5. -   11. Gottschalk, M., R. Higgins, M. Jacques, K. R. Mittal, and J.     Henrichsen. 1989. Description of 14 new capsular types of     Streptococcus suis. J Clin Microbiol 27:2633-6. -   12. Gottschalk, M., A. Lebrun, H. Wisselink, J. D. Dubreuil, H.     Smith, and U. Vecht. 1998. Production of virulence-related proteins     by Canadian strains of Streptococcus suis capsular type 2. Can J Vet     Res 62:75-9. -   13. Gottschalk, M., and M. Segura. 2000. The pathogenesis of the     meningitis caused by Streptococcus suis: the unresolved questions.     Vet Microbiol 76:259-72. -   14. Higgins, R., and M. Gottschalk. 1998. Distribution of     Streptococcus suis capsular types in 1997. Can Vet J 39:299-300. -   15. Higgins, R., M. Gottschalk, M. Boudreau, A. Lebrun, and J.     Henrichsen. 1995. Description of six new capsular types (29-34) of     Streptococcus suis. J Vet Diagn Invest 7:405-6. -   16. Higgins, R., M. Gottschalk. 2005. Streptococcal diseases (In     press). In B. E. Straw, S. D'Allaire, W. L. Mengeling, and D. J.     Taylor (9th ed), Diseases of swine. Iowa State University Press,     Ames. -   17. Hill, J. E., M. Gottschalk, R. Brousseau, J. Harel, S. M.     Hemmingsen, and S. H. Goh. 2005. Biochemical analysis, cpn60 and 16S     rDNA sequence data indicate that Streptococcus suis serotypes 32 and     34, isolated from pigs, are Streptococcus orisratti. Vet Microbiol     107:63-9. -   18. Holt, M. E., M. R. Enright, and T. J. Alexander. 1988.     Immunisation of pigs with live cultures of Streptococcus suis     type 2. Res Vet Sci 45:349-52. -   19. Ioannou, X. P., P. Griebel, R. Hecker, L. A. Babiuk, and S. van     Drunen Littel-van den Hurk. 2002. The immunogenicity and protective     efficacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are     increased by formulation with CpG oligodeoxynucleotides. J Virol     76:9002-10. -   20. Jacobs, A. A., A. J. van den Berg, and P. L. Loeffen. 1996.     Protection of experimentally infected pigs by suilysin, the     thiol-activated haemolysin of Streptococcus suis. Vet Rec 139:225-8. -   21. Laemmli, U. K. 1970. Cleavage of structural proteins during the     assembly of the head of bacteriophage T4. Nature 227:680-5. -   22. Lefeber, D. J., B. Benaissa-Trouw, J. F. Vliegenthart, J. P.     Kamerling, W. T. Jansen, K. Kraaijeveld, and H. Snippe. 2003.     Th1-directing adjuvants increase the immunogenicity of     oligosaccharide-protein conjugate vaccines related to Streptococcus     pneumoniae type 3. Infect Immun 71:6915-20. -   23. Lofthouse, S. A., A. E. Andrews, A. D. Nash, and V. M.     Bowles. 1995. Humoral and cellular responses induced by     intradermally administered cytokine and conventional adjuvants.     Vaccine 13:1131-7. -   24. Lynch, J. M., D. E. Briles, and D. W. Metzger. 2003. Increased     protection against pneumococcal disease by mucosal administration of     conjugate vaccine plus interleukin-12. Infect Immun 71:4780-8. -   25. Marques, M. B., D. L. Kasper, A. Shroff, F. Michon, H. J.     Jennings, and M. R. Wessels. 1994. Functional activity of antibodies     to the group B polysaccharide of group B streptococci elicited by a     polysaccharide-protein conjugate vaccine. Infect Immun 62:1593-9. -   26. McArthur, J., E. Medina, A. Mueller, J. Chin, B. J.     Currie, K. S. Sriprakash, S. R. Talay, G. S. Chhatwal, and M. J.     Walker. 2004. Intranasal vaccination with streptococcal fibronectin     binding protein Sfb1 fails to prevent growth and dissemination of     Streptococcus pyogenes in a murine skin infection model. Infect     Immun 72:7342-5. -   27. Miyaji, E. N., D. M. Ferreira, A. P. Lopes, M. C.     Brandileone, W. O. Dias, and L. C. Leite. 2002. Analysis of serum     cross-reactivity and cross-protection elicited by immunization with     DNA vaccines against Streptococcus pneumoniae expressing PspA     fragments from different clades. Infect Immun 70:5086-90. -   28. Nichani, A. K., R. S. Kaushik, A. Mena, Y. Popowych, D.     Dent, H. G. Townsend, G. Mutwiri, R. Hecker, L. A. Babiuk, and P. J.     Griebel. 2004. CpG oligodeoxynucleotide induction of antiviral     effector molecules in sheep. Cell Immunol 227:24-37. -   29. Okwumabua, O., O. Abdelmagid, and M. M. Chengappa. 1999.     Hybridization analysis of the gene encoding a hemolysin (suilysin)     of Streptococcus suis type 2: evidence for the absence of the gene     in some isolates. FEMS Microbiol Lett 181:113-21. -   30. Pallares, F. J., C. S. Schmitt, J. A. Roth, R. B. Evans, J. M.     Kinyon, and P. G. Halbur. 2004. Evaluation of a ceftiofur-washed     whole cell Streptococcus suis bacterin in pigs. Can J Vet Res     68:236-40. -   31. Perch, B., K. B. Pedersen, and J. Henrichsen. 1983. Serology of     capsulated streptococci pathogenic for pigs: six new serotypes of     Streptococcus suis. J Clin Microbiol 17:993-6. -   32. Segura, M., M. Gottschalk, and M. Olivier. 2004. Encapsulated     Streptococcus suis inhibits activation of signaling pathways     involved in phagocytosis. Infect Immun 72:5322-30. -   33. Serhir, B., D. Dugourd, M. Jacques, R. Higgins, and J.     Harel. 1997. Cloning and characterization of a dextranase gene     (dexS) from Streptococcus suis. Gene 190:257-61. -   34. Sheoran, A. S., S. Artiushin, and J. F. Timoney. 2002. Nasal     mucosal immunogenicity for the horse of a SeM peptide of     Streptococcus equi genetically coupled to cholera toxin. Vaccine     20:1653-9. -   35. Torremorell, M., C. Pijoan, and S. Dee. 1999. Experimental     exposure of young pigs using a pathogenic strain of Streptococcus     suis serotype 2 and evaluation of this method for disease     prevention. Can J Vet Res 63:269-75. -   36. Trottier, S., R. Higgins, G. Brochu, and M. Gottschalk. 1991. A     case of human endocarditis due to Streptococcus suis in North     America. Rev Infect Dis 13:1251-2. -   37. Willson, P. J., A. Rossi-Campos, and A. A. Potter. 1995. Tissue     reaction and immunity in swine immunized with Actinobacillus     pleuropneumoniae vaccines. Can J Vet Res 59:299-305. -   38. Wisselink, H. J., N. Stockhofe-Zurwieden, L. A. Hilgers,     and H. E. Smith. 2002. Assessment of protective efficacy of live and     killed vaccines based on a non-encapsulated mutant of Streptococcus     suis serotype 2. Vet Microbiol 84:155-68. -   39. Wisselink, H. J., U. Vecht, N. Stockhofe-Zurwieden, and H. E.     Smith. 2001. Protection of pigs against challenge with virulent     Streptococcus suis serotype 2 strains by a muramidase-released     protein and extracellular factor vaccine. Vet Rec 148:473-7. -   40. Wortham, C., L. Grinberg, D. C. Kaslow, D. E. Briles, L. S.     McDaniel, A. Lees, M. Flora, C. M. Snapper, and J. J. Mond. 1998.     Enhanced protective antibody responses to PspA after intranasal or     subcutaneous injections of PspA genetically fused to     granulocyte-macrophage colony-stimulating factor or interleukin-2.     Infect Immun 66:1513-20. -   41. Yang, B., W. Zhu, L. B. Johnson, and F. F. White. 2000. The     virulence factor AvrXa7 of Xanthomonas oryzae pv. oryzae is a type     III secretion pathway-dependent nuclear-localized double-stranded     DNA-binding protein. Proc Natl Acad Sci USA 97:9807-12. -   42. Pollack, M., N. L. Koles, M. J. Preston, B. J. Brown, and G. B.     Pier. 1995. Functional properties of isotype-switched immunoglobulin     M (IgM) and IgG monoclonal antibodies to Pseudomonas aeruginosa     lipopolysaccharide. Infect Immun 63:4481-8. -   43. Unkeless, J. C., E. Scigliano, and V. H. Freedman. 1988.     Structure and function of human and murine receptors for IgG. Annu     Rev Immunol 6:251-81. -   44. Serhir, B., D. Dugourd, M. Jacques, R. Higgins, and J.     Harel. 1997. Cloning and characterization of a dextranase gene     (dexS) from Streptococcus suis. Gene 190:257-61. 

The invention claimed is:
 1. An isolated polypeptide comprising an amino acid sequence having at least 75% identity to the amino acid sequence set forth in SEQ ID NO: 1 or in SEQ ID NO:
 4. 2. The isolated polypeptide of claim 1, comprising at least one repetitive amino acid sequence consisting of the amino acid sequence Xaa₁ Ser Xaa₃ Xaa₄ Xaa₅ Met Xaa₇ Xaa₈ Xaa₉ Xaa₁₀ Xaa₁₁ Xaa₁₂ Xaa₁₃ Xaa₁₄ Xaa₁₅ Xaa₁₆ Pro Xaa₁₈ Xaa₁₉ Gln Met Xaa₂₂ Asn Lys Glu Xaa₂₆ Xaa₂₇ Xaa₂₈ Xaa₂₉ Xaa₃₀ (SEQ ID NO 9) wherein Xaa₁ is Val, Thr or Ile; Xaa₃ is Lys or Glu; Xaa₄ is Lys or Glu; Xaa₅ is Ala or Gln; Xaa₇ is Thr or Pro; Xaa₈ is Gly, Ser or Val; Xaa₉ is Lys, Val, Ile or Asn; Xaa₁₀ is Glu or Val; Xaa₁₁ is Lys or Asn; Xaa₁₂ is Gly, Glu or Asp; Xaa₁₃ is Asn or Met; Xaa₁₄ is Ile, Ala or Val; Xaa₁₅ is Glu or Val; Xaa₁₆ is Pro or Thr; Xaa₁₈ is Glu or Gln; Xaa₁₉ is Lys or Glu; Xaa₂₂ is Thr or Ala; Xaa₂₆ is Lys or Asn; Xaa₂₇ is Asp or Glu; Xaa₂₈ is Asn or Lys; Xaa₂₉ is Ile or Val and Xaa₃₀ is Glu or Val.
 3. The isolated polypeptide of claim 1, comprising the amino acid sequence as set forth in SEQ ID NO
 10. 4. The isolated polypeptide of claim 1, comprising an amino acid having at least 85% identity to the amino acid sequence set forth in SEQ ID NO 1 or in SEQ ID NO
 4. 5. The isolated polypeptide of claim 1, comprising an amino acid sequence having at least 95% identity to the amino acid sequence set forth in SEQ ID NO
 1. 6. The isolated polypeptide of claim 1, comprising an amino acid sequence having at least 95% identity to the amino acid sequence set forth in SEQ ID NO
 4. 7. The isolated polypeptide of claim 1, wherein it elicits a protective response to a Streptococcus suis strain challenge when administered to an animal.
 8. The isolated polypeptide of claim 3, comprising at least one repetitive amino acid sequence consisting of the amino acid sequence Xaa₁ Ser Xaa₃ Xaa₄ Xaa₅ Met Xaa₇ Xaa₈ Xaa₉ Xaa₁₀ X₁₁ Xaa₁₂ Xaa₁₃ Xaa₁₄ Xaa₁₅ Xaa₁₆ Pro Xaa₁₈ Xaa₁₉ Gln Met Xaa₂₂ Asn Lys Glu Xaa₂₆ Xaa₂₇ Xaa₂₈ Xaa₂₉ Xaa₃₀ (SEQ ID NO 9) wherein Xaa₁ is Val, Thr or Ile; Xaa₃ is Lys or Glu; Xaa₄ is Lys or Glu; Xaa₅ is Ala or Gln; Xaa₇ is Thr or Pro; Xaa₈ is Gly, Ser or Val; Xaa₉ is Lys, Val, Ile or Asn; Xaa₁₀ is Glu or Val; Xaa₁₁ is Lys or Asn; Xaa₁₂ is Gly, Glu or Asp; Xaa₁₃ is Asn or Met; Xaa₁₄ is Ile, Ala or Val; Xaa₁₅ is Glu or Val; Xaa₁₆ is Pro or Thr; Xaa₁₈ is Glu or Gln; Xaa₁₉ is Lys or Glu; Xaa₂₂ is Thr or Ala; Xaa₂₆ is Lys or Asn; Xaa₂₇ is Asp or Glu; Xaa₂₈ is Asn or Lys; Xaa₂₉ is Ile or Val and Xaa₃₀ is Glu or Val.
 9. The isolated polypeptide of claim 4, comprising at least one repetitive amino acid sequence consisting of the amino acid sequence Xaa₁ Ser Xaa₃ Xaa₄ Xaa₅ Met Xaa₇ Xaa₈ Xaa₉ Xaa₁₀ Xaa₁₁ Xaa₁₂ Xaa₁₃ Xaa₁₄ Xaa₁₅ Xaa₁₆ Pro Xaa₁₈ Xaa₁₉ Gln Met Xaa₂₂ Asn Lys Glu Xaa₂₆ Xaa₂₇ Xaa₂₈ Xaa₂₉ Xaa₃₀ (SEQ ID NO 9) wherein Xaa₁ is Val, Thr or Ile; Xaa₃ is Lys or Glu; Xaa₄ is Lys or Glu; Xaa₅ is Ala or Gln; Xaa₇ is Thr or Pro; Xaa₈ is Gly, Ser or Val; Xaa₉ is Lys, Val, Ile or Asn; Xaa₁₀ is Glu or Val; Xaa₁₁ is Lys or Asn; Xaa₁₂ is Gly, Glu or Asp; Xaa₁₃ is Asn or Met; Xaa₁₄ is Ile, Ala or Val; Xaa₁₅ is Glu or Val; Xaa₁₆ is Pro or Thr; Xaa₁₈ is Glu or Gln; Xaa₁₉ is Lys or Glu; Xaa₂₂ is Thr or Ala; Xaa₂₆ is Lys or Asn; Xaa₂₇ is Asp or Glu; Xaa₂₈ is Asn or Lys; Xaa₂₉ is Ile or Val and Xaa₃₀ is Glu or Val.
 10. The isolated polypeptide of claim 5, comprising at least one repetitive amino acid sequence consisting of the amino acid sequence Xaa₁ Ser Xaa₃ Xaa₄ Xaa₅ Met Xaa₇ Xaa₈ Xaa₉ Xaa₁₀ Xaa₁₁ Xaa₁₂ Xaa₁₃ Xaa₁₄ Xaa₁₅ Xaa₁₆ Pro Xaa₁₈ Xaa₁₉ Gln Met Xaa₂₂ Asn Lys Glu Xaa₂₆ Xaa₂₇ Xaa₂₈ Xaa₂₉ Xaa₃₀ (SEQ ID NO 9) wherein Xaa₁ is Val, Thr or Ile; Xaa₃ is Lys or Glu; Xaa₄ is Lys or Glu; Xaa₅ is Ala or Gln; Xaa₇ is Thr or Pro; Xaa₈ is Gly, Ser or Val; Xaa₉ is Lys, Val, Ile or Asn; Xaa₁₀ is Glu or Val; Xaa₁₁ is Lys or Asn; Xaa₁₂ is Gly, Glu or Asp; Xaa₁₃ is Asn or Met; Xaa₁₄ is Ile, Ala or Val; Xaa₁₅ is Glu or Val; Xaa₁₆ is Pro or Thr; Xaa₁₈ is Glu or Gln; Xaa₁₉ is Lys or Glu; Xaa₂₂ is Thr or Ala; Xaa₂₆ is Lys or Asn; Xaa₂₇ is Asp or Glu; Xaa₂₈ is Asn or Lys; Xaa₂₉ is Ile or Val and Xaa₃₀ is Glu or Val.
 11. The isolated polypeptide of claim 6, comprising at least one repetitive amino acid sequence consisting of the amino acid sequence Xaa₁ Ser Xaa₃ Xaa₄ Xaa₅ Met Xaa₇ Xaa₈ Xaa₉ Xaa₁₀ Xaa₁₁ Xaa₁₂ Xaa₁₃ Xaa₁₄ Xaa₁₅ Xaa₁₆ Pro Xaa₁₈ Xaa₁₉ Gln Met Xaa₂₂ Asn Lys Glu Xaa₂₆ Xaa₂₇ Xaa₂₈ Xaa₂₉ Xaa₃₀ (SEQ ID NO 9) wherein Xaa₁ is Val, Thr or Ile; Xaa₃ is Lys or Glu; Xaa₄ is Lys or Glu; Xaa₅ is Ala or Gln; Xaa₇ is Thr or Pro; Xaa₈ is Gly, Ser or Val; Xaa₉ is Lys, Val, Ile or Asn; Xaa₁₀ is Glu or Val; Xaa₁₁ is Lys or Asn; Xaa₁₂ is Gly, Glu or Asp; Xaa₁₃ is Asn or Met; Xaa₁₄ is Ile, Ala or Val; Xaa₁₅ is Glu or Val; Xaa₁₆ is Pro or Thr; Xaa₁₈ is Glu or Gln; Xaa₁₉ is Lys or Glu; Xaa₂₂ is Thr or Ala; Xaa₂₆ is Lys or Asn; Xaa₂₇ is Asp or Glu; Xaa₂₈ is Asn or Lys; Xaa₂₉ is Ile or Val and Xaa₃₀ is Glu or Val.
 12. The isolated polypeptide of claim 1, comprising an amino acid sequence having 100% identity to the amino acid sequence set forth in SEQ ID NO
 1. 13. The isolated polypeptide of claim 1, comprising an to amino acid sequence having 100% identity to the amino acid sequence set forth in SEQ ID NO
 4. 14. An isolated polypeptide, comprising an amino acid sequence having at least 95% identity to the amino acid sequence set forth in SEQ ID NO
 2. 15. The isolated polypeptide of claim 14, comprising an amino acid sequence having 100% identity to the amino acid sequence set forth in SEQ ID NO
 2. 16. An isolated polypeptide, comprising an amino acid sequence having at least 95% identity to the amino acid zo sequence set forth in SEQ ID NO
 3. 17. The isolated polypeptide of claim 16, comprising an amino acid sequence having 100% identity to the amino acid sequence set forth in SEQ ID NO
 3. 18. A composition comprising an acceptable carrier and at least one of the following elements: a polypeptide as defined in any one of claims 1, 2, 3, 4, 5, 6, 7, and 8 to
 17. 19. A composition for eliciting an immune response to Streptococcus or treating Streptococcus suis-associated diseases or infection caused by S. suis, comprising an acceptable carrier and at least one of the following elements: a polypeptide as defined in any one of claims 1, 2, 3, 4, 5, 6, 7, and 8 to
 17. 20. The composition of claim 19, further comprising an adjuvant.
 21. A vaccine comprising a polypeptide having at least 15 contiguous amino acid residues of the amino acid sequence of SEQ ID NO: 4, and an adjuvant.
 22. The vaccine of claim 21, wherein the polypeptide has at least 25 contiguous amino acid residues of the amino acid sequence of SEQ ID NO:
 4. 23. The vaccine of claim 21, wherein the polypeptide has at least 35 contiguous amino acid residues of the amino acid sequence of SEQ ID NO:
 4. 24. The vaccine of claim 21, wherein the polypeptide further includes at the C-terminal end thereof the amino acid sequence of SEQ ID NO:
 9. 25. The vaccine of claim 24, wherein the amino acid sequence of SEQ ID NO: 9 is a first repetitive sequence of a plurality of repetitive sequences of SEQ ID NO:
 9. 26. The vaccine of claim 21, in freeze-dried form.
 27. The vaccine of claim 21, in the form of an injectable preparation.
 28. The vaccine of claim 21, in a form suitable for injection, infusion or per os administration.
 29. The vaccine of claim 21, further including an acceptable carrier.
 30. The vaccine of claim 21, wherein the adjuvant includes Quil A, a cytokine, an oil and water emulsion, aluminum hydroxide, glucan, dextran sulfate, iron oxide, sodium alginate, poly amino acids, co-polymers of amino acids, saponin, paraffin oil, muramyl dipeptide, or CpG oligonucleotides.
 31. The vaccine of claim 21, wherein the oil and water emulsion includes complete Freund's adjuvant or incomplete Freund's adjuvant.
 32. The vaccine of claim 30, wherein the adjuvant includes Quil A.
 33. An isolated polypeptide fragment of the polypeptide of SEQ ID NO: 4, having at least 15 contiguous amino acid residues of the amino acid sequence of SEQ ID NO: 4, which is effective for eliciting an immune response to Streptococcus or treating Streptococcus suis-associated diseases or infection caused by S. suis.
 34. The isolated polypeptide fragment of claim 33, having at least 25 contiguous amino acid residues of the amino acid sequence of SEQ ID NO:
 4. 35. The isolated polypeptide fragment of claim 33, having at least 35 contiguous amino acid residues of the amino acid sequence of SEQ ID NO:
 4. 36. The isolated polypeptide fragment of claim 33, further including a fusion tag at the N-terminal end thereof.
 37. The isolated polypeptide fragment of claim 33, further including at the C-terminal end thereof a repetitive sequence consisting of the amino acid sequence of SEQ ID NO:
 9. 38. The isolated polypeptide fragment of claim 37, wherein said repetitive sequence is a first repetitive sequence of a plurality of said repetitive sequence.
 39. The isolated polypeptide fragment of claim 34, further including at the C-terminal end thereof a repetitive sequence consisting of the amino acid sequence of SEQ ID NO:
 9. 40. The isolated polypeptide fragment of claim 39, wherein said repetitive sequence is a first repetitive sequence of a plurality of said repetitive sequence.
 41. The isolated polypeptide fragment of claim 35, further including at the C-terminal end thereof a repetitive sequence consisting of the amino acid sequence of SEQ ID NO:
 9. 42. The isolated polypeptide fragment of claim 41, wherein said repetitive sequence is a first repetitive sequence of a plurality of said repetitive sequence.
 43. The vaccine of claim 21, wherein the adjuvant includes carbohydrate, virosomes, structured complex of saponins and lipids, polymeric microsphere, killed bacteria, bacteria derivatives, toxin, peptidoglycan, lipopolysaccharide, trehalose dimycolate, or squalene. 